Pancreatic Cancer Research

ResearcherMie UniversityActive in the last 2 years

Yasuhiro Murata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5997-4342; OpenAlex author ID A5061737621. Sources: OpenAlex.

Their work

Papers
26 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 4 papers · 2020: none · 2021: 3 papers · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 5 papers · 2026: 1 paper

Papers 26

  1. Prognostic Significance of Portal Vein Tumor Thrombus in Pancreatic Ductal Adenocarcinoma Treated With Chemoradiotherapy. Co-author DOI 10.1002/ags3.70186↗
  2. Long-term survival analysis based on tumor location in patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy following neoadjuvant chemor… Co-author DOI 10.1007/s00423-025-03609-8↗
  3. Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. Co-author DOI 10.1016/j.suronc.2025.102269↗
  4. Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradi… Co-author DOI 10.1097/md.0000000000042441↗
  5. Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resection After Preoperative Chemoradiotherap… Co-author DOI 10.1097/mpa.0000000000002440↗
  6. Impact of Surgical Resection After Induction Gemcitabine Plus S-1-Based Chemoradiotherapy in Patients with Locally Advanced Pancreatic Ductal Adenocarcinoma: A… Co-author DOI 10.3390/cancers17061048↗
  7. Peritoneal washing cytology status as a crucial prognostic determinant in patients with localized pancreatic ductal adenocarcinoma who underwent curative-inten… First author DOI 10.1371/journal.pone.0309834↗
  8. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemor… Co-author DOI 10.1016/j.hpb.2023.06.015↗
  9. Concomitant splenic artery ligation has no preventive effect on left-sided portal hypertension following pancreaticoduodenectomy with the resection of the port… Co-author DOI 10.1002/ags3.12545↗
  10. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator … Co-author DOI 10.1097/sla.0000000000004148↗
  11. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preopera… Co-author DOI 10.1371/journal.pone.0264573↗
  12. Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with localized pancreatic ductal adenocarcinom… Co-author DOI 10.21203/rs.3.rs-2229927/v1↗
  13. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic… Co-author DOI 10.1016/j.pan.2021.08.011↗
  14. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Con… Co-author DOI 10.1097/mpa.0000000000001902↗
  15. Improving the Prognosis of Pancreatic Cancer Through Early Detection: Protocol for a Prospective Observational Study. Co-author DOI 10.2196/26898↗
  16. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resec… Co-author DOI 10.1016/j.pan.2019.01.020↗
  17. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With S… Co-author DOI 10.1097/mpa.0000000000001227↗
  18. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing … First author DOI 10.1155/2019/5738614↗
  19. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Du… Co-author DOI 10.3390/cancers11040514↗
  20. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… First author DOI 10.1097/mpa.0000000000001022↗
  21. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus o… Co-author DOI 10.3390/cancers10030065↗
  22. [I. The Efficacy of Preoperative Adjuvant Treatment for Pancreatic Ductal Adenocarcinoma Based on the Resectability Criteria according to JPS 7th]. Co-author PMID 29066676↗
  23. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Cli… Co-author DOI 10.1097/mpa.0000000000000597↗
  24. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of th… Co-author DOI 10.1097/mpa.0000000000000059↗
  25. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoper… Co-author DOI 10.1007/s00534-011-0440-3↗
  26. Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Co-author DOI 10.1097/mpa.0b013e3182236442↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masashi Kishiwada · 26 shared papers, 2012–2026 · strength 3.30
  2. Shugo Mizuno · 25 shared papers, 2012–2026 · strength 3.21
  3. Aoi Hayasaki · 22 shared papers, 2017–2026 · strength 3.16
  4. Naohisa Kuriyama · 21 shared papers, 2016–2026 · strength 3.01
  5. Takahiro Ito · 11 shared papers, 2018–2025 · strength 1.93
  6. Kazuyuki Gyoten · 11 shared papers, 2021–2025 · strength 1.78
  7. Shuji Isaji · 17 shared papers, 2012–2023 · strength 1.43
  8. Hiroyuki Sakurai · 14 shared papers, 2012–2022 · strength 1.21
  9. Benson Kaluba · 6 shared papers, 2022–2025 · strength 1.14
  10. Toru Shinkai · 6 shared papers, 2017–2025 · strength 0.88
  11. Hiroyuki Kato · 8 shared papers, 2017–2022 · strength 0.68
  12. Miki Usui · 2 shared papers, 2025–2026 · strength 0.49
  13. Yoshinori Azumi · 6 shared papers, 2018–2019 · strength 0.47
  14. Hiroyuki Inoue · 5 shared papers, 2012–2021 · strength 0.24
  15. Takuya Yuge · 1 shared paper, 2024 · strength 0.20
  16. Masatoshi Watanabe · 1 shared paper, 2025 · strength 0.20
  17. Junya Tsuboi · 2 shared papers, 2016–2021 · strength 0.15
  18. Reiko Yamada · 2 shared papers, 2016–2021 · strength 0.15
  19. Taizo Shiraishi · 4 shared papers, 2012–2016 · strength 0.14
  20. Yoshihiro Kondo · 1 shared paper, 2021 · strength 0.10
  21. Satoshi Tamaru · 1 shared paper, 2021 · strength 0.10
  22. Taijiro TAKEUCHI · 1 shared paper, 2019 · strength 0.08
  23. Warakorn Jaseanchiun · 1 shared paper, 2019 · strength 0.08
  24. Ken Ichikawa · 1 shared paper, 2019 · strength 0.08
  25. Misao Yoneda · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.